Jan Peter Rake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jan Peter Rake has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
G. Peter A. Smit
Beatrix Children's Hospital, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The NetherlandsTel.: +31-50-3616161; Fax: +31-50-3614235
4 shared publicationsAnnelies M. Ten Berge
Department of Medical Genetics, University of Groningen, The Netherlands
3 shared publicationsEdwin Verlind
Department of Medical Genetics, University of Groningen, The Netherlands
3 shared publicationsGepke Visser
Beatrix Children's Hospital, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The NetherlandsTel.: +31-50-3616161; Fax: +31-50-3614235
3 shared publicationsKlary E. Niezen-Koning
Beatrix Children's Hospital, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The NetherlandsTel.: +31-50-3616161; Fax: +31-50-3614235
3 shared publicationsCharles H.C.M. Buys
Department of Medical Genetics, University of Groningen, The Netherlands
2 shared publications
Latest Publications
- 1 June 2003
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 26 (4) , 371-384
Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: A cross‐sectional and longitudinal study
The occurrence of (symptoms related to) osteopenia is a known complication in glycogen storage disease type Ia (GSD Ia) patients. However, only limited information is available about bone mineral density (BMD). Using dual energy x‐ray absorptiometry, we studied both cross‐sectional and longitudinal lumbar spine areal BMD (BMDareal in g/cm2), areal BMD corrected for delayed bone maturation (BMDbone age in g/cm2), and volumetric BMD (BMDvol in g/cm3). Prepubertal GSD Ia patients (n = 8) had normal BMD (median z‐scores BMDareal ‐0.6, BMDbone age ‐0.5 and BMDvol ‐ 0.5), whereas adolescent patients (n = 12) and adult patients (n = 9) had significantly reduced BMD (BMDareal ‐2.3, BMDbone age ‐1.6, BMDvol ‐2.0, and BMDareal ‐1.9, BMDvol‐1.5, respectively). Our longitudinal study, showing a stable BMDareal but a trend to a decrease in BMDvol in prepubertal patients during follow‐up, did not clarify whether the difference in BMD between prepubertal and adolescent/adult patients reflects a diminished accretion of BMD during childhood or reflects historica l differences in treatment. In adolescent and adult GSD Ia patients, BMDareal and BMDvol were reduced but stable during follow‐up. Especially patients with delayed bone maturation were at risk for reduced BMD. No correlation between parameters of metabolic control and BMD could be detected. Daily calcium intake was within recommended allowances ranges. Abnormal biochemical results included hypomagnesaemia (29%), hypercalciuria (34%) and reduced tubular resorption of phosphate (21%).Although the underlying pathophysiology of reduced BMD in GSD Ia remains unsolved, metabolic control should be optimized to correct as much as possible metabolic and endocrine abnormalitie s that may influence both bone matrix formation and bone mineral accretion.
- 1 June 2003
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 26 (4) , 371-384
Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: A cross‐sectional and longitudinal study
The occurrence of (symptoms related to) osteopenia is a known complication in glycogen storage disease type Ia (GSD Ia) patients. However, only limited information is available about bone mineral density (BMD). Using dual energy x‐ray absorptiometry, we studied both cross‐sectional and longitudinal lumbar spine areal BMD (BMDareal in g/cm2), areal BMD corrected for delayed bone maturation (BMDbone age in g/cm2), and volumetric BMD (BMDvol in g/cm3). Prepubertal GSD Ia patients (n = 8) had normal BMD (median z‐scores BMDareal ‐0.6, BMDbone age ‐0.5 and BMDvol ‐ 0.5), whereas adolescent patients (n = 12) and adult patients (n = 9) had significantly reduced BMD (BMDareal ‐2.3, BMDbone age ‐1.6, BMDvol ‐2.0, and BMDareal ‐1.9, BMDvol‐1.5, respectively). Our longitudinal study, showing a stable BMDareal but a trend to a decrease in BMDvol in prepubertal patients during follow‐up, did not clarify whether the difference in BMD between prepubertal and adolescent/adult patients reflects a diminished accretion of BMD during childhood or reflects historica l differences in treatment. In adolescent and adult GSD Ia patients, BMDareal and BMDvol were reduced but stable during follow‐up. Especially patients with delayed bone maturation were at risk for reduced BMD. No correlation between parameters of metabolic control and BMD could be detected. Daily calcium intake was within recommended allowances ranges. Abnormal biochemical results included hypomagnesaemia (29%), hypercalciuria (34%) and reduced tubular resorption of phosphate (21%).Although the underlying pathophysiology of reduced BMD in GSD Ia remains unsolved, metabolic control should be optimized to correct as much as possible metabolic and endocrine abnormalitie s that may influence both bone matrix formation and bone mineral accretion.
- 1 February 2003
- Published by Springer Nature in Tijdschrift voor kindergeneeskunde
- Vol. 71 (6) , 40-41
Glycogen storage disease type I: clinical, biochemical and genetic aspects, and implications for treatment and follow-up
- 1 February 2003
- Published by Springer Nature in Tijdschrift voor kindergeneeskunde
- Vol. 71 (6) , 40-41
Glycogen storage disease type I: clinical, biochemical and genetic aspects, and implications for treatment and follow-up
- 9 June 2000
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 159 (7) , 523-526
End-stage liver disease as the only consequence of a mitochondrial respiratory chain deficiency: no contra-indication for liver transplantation
The prerequisite for liver transplantation as a therapeutic option for inherited metabolic diseases should be that the enzyme defect, being responsible for the major clinical (hepatic and/or extra-hepatic) abnormalities, is localised in the liver. Furthermore, no adequate dietary or pharmacological treatment should be available or such treatment should have an unacceptable influence on the quality of life. We report an infant, who developed end-stage liver disease with persistent lactic acidaemia in his first months of life. Analysis of the mitochondrial respiratory chain in liver tissue revealed a combined partial complex I and IV deficiency. No extra-hepatic involvement could be demonstrated by careful screening for multiple organ involvement, including analysis of the mitochondrial respiratory chain in muscle tissue and cultured skin fibroblasts. The boy received a reduced size liver graft at the age of 8 months. He recovered successfully. Almost 5 years after transplantation he is in good clinical condition. No clinical or biochemical signs of any organ dysfunction have been demonstrated. The considerations on which basis it was decided that there was no contra-indication to perform liver transplantation in this patient are discussed. Conclusion The possibility of a mitochondrial respiratory chain deficiency should be considered in liver disease of unknown origin prior to liver transplantation. Liver transplantation is a therapeutic option in mitochondrial respiratory chain deficiency-based end-stage liver disease provided that extra-hepatic involvement is carefully excluded.
- 9 June 2000
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 159 (7) , 523-526
End-stage liver disease as the only consequence of a mitochondrial respiratory chain deficiency: no contra-indication for liver transplantation
The prerequisite for liver transplantation as a therapeutic option for inherited metabolic diseases should be that the enzyme defect, being responsible for the major clinical (hepatic and/or extra-hepatic) abnormalities, is localised in the liver. Furthermore, no adequate dietary or pharmacological treatment should be available or such treatment should have an unacceptable influence on the quality of life. We report an infant, who developed end-stage liver disease with persistent lactic acidaemia in his first months of life. Analysis of the mitochondrial respiratory chain in liver tissue revealed a combined partial complex I and IV deficiency. No extra-hepatic involvement could be demonstrated by careful screening for multiple organ involvement, including analysis of the mitochondrial respiratory chain in muscle tissue and cultured skin fibroblasts. The boy received a reduced size liver graft at the age of 8 months. He recovered successfully. Almost 5 years after transplantation he is in good clinical condition. No clinical or biochemical signs of any organ dysfunction have been demonstrated. The considerations on which basis it was decided that there was no contra-indication to perform liver transplantation in this patient are discussed. Conclusion The possibility of a mitochondrial respiratory chain deficiency should be considered in liver disease of unknown origin prior to liver transplantation. Liver transplantation is a therapeutic option in mitochondrial respiratory chain deficiency-based end-stage liver disease provided that extra-hepatic involvement is carefully excluded.
- 9 April 2000
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 159 (5) , 322-330
Glycogen storage disease type Ia: recent experience with mutation analysis, a summary of mutations reported in the literature and a newly developed diagnostic flowchart
We studied the glucose-6-phosphatase (G6Pase) gene of 30 unrelated glycogen storage disease type Ia (GSD Ia) patients using single strand conformational polymorphism (SSCP) prior to automated sequencing of exons revealing an aberrant SSCP pattern. In all patients we could identify mutations on both alleles of the G6Pase gene, indicating that this method is a reliable procedure. A total of 14 different mutations were identified. R83C (16/60), 158delC (12/60), Q347X (7/60), R170X (6/60) and ΔF327 (4/60) were found most frequently. Nine other mutations accounted for the other 15 mutant alleles. Two DNA-based prenatal diagnoses were performed successfully. At present, 56 mutations in the G6Pase gene have been reported in 300 unrelated GSD Ia patients and an overview of these mutations is presented. Evidence for a clear genotype-phenotype correlation could be established neither from our data nor from those in the literature. With increased knowledge about the genetic basis of GSD Ia and GSD Ib and the high detection rate of mutations, it is our opinion that the diagnoses GSD Ia and GSD Ib can usually be based on clinical and biochemical abnormalities combined with mutation analysis instead of enzyme assays in liver tissue obtained by biopsy. A newly developed flowchart for the diagnosis of GSD I is presented. Conclusion Increased knowledge of the genetic basis of glycogen storage disease type I provides a DNA-based diagnosis, prenatal DNA-based diagnosis in chorionic villus samples and carrier detection.
- 9 April 2000
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 159 (5) , 322-330
Glycogen storage disease type Ia: recent experience with mutation analysis, a summary of mutations reported in the literature and a newly developed diagnostic flowchart
We studied the glucose-6-phosphatase (G6Pase) gene of 30 unrelated glycogen storage disease type Ia (GSD Ia) patients using single strand conformational polymorphism (SSCP) prior to automated sequencing of exons revealing an aberrant SSCP pattern. In all patients we could identify mutations on both alleles of the G6Pase gene, indicating that this method is a reliable procedure. A total of 14 different mutations were identified. R83C (16/60), 158delC (12/60), Q347X (7/60), R170X (6/60) and ΔF327 (4/60) were found most frequently. Nine other mutations accounted for the other 15 mutant alleles. Two DNA-based prenatal diagnoses were performed successfully. At present, 56 mutations in the G6Pase gene have been reported in 300 unrelated GSD Ia patients and an overview of these mutations is presented. Evidence for a clear genotype-phenotype correlation could be established neither from our data nor from those in the literature. With increased knowledge about the genetic basis of GSD Ia and GSD Ib and the high detection rate of mutations, it is our opinion that the diagnoses GSD Ia and GSD Ib can usually be based on clinical and biochemical abnormalities combined with mutation analysis instead of enzyme assays in liver tissue obtained by biopsy. A newly developed flowchart for the diagnosis of GSD I is presented. Conclusion Increased knowledge of the genetic basis of glycogen storage disease type I provides a DNA-based diagnosis, prenatal DNA-based diagnosis in chorionic villus samples and carrier detection.
- Open Access
- 22 March 2000
- Published by Hindawi Limited in Human Mutation
- Vol. 15 (4) , 381
Identification of a novel mutation (867delA) in the glucose-6-phosphatase gene in two siblings with glycogen storage disease type Ia with different phenotypes Communicated by: Mark H. Paalman Online Citation: Human Mutation, Mutation in Brief #304 (1999) Online http://journals.wiley.com/1059-7794/pdf/mutation/304.pdf
We identified a novel mutation (867delA) in the glucose-6-phosphatase gene of two siblings with glycogen storage disease type Ia. Although both siblings share the same mutations, their phenotype regarding adult height and hepatomegaly differs. In glycogen storage disease type Ia, substantial heterogeneity in phenotype is observed. So far, no evidence for a clear genotype-phenotype correlation has been found. Hum Mutat 15:381, 2000.
- 22 March 2000
- Published by Hindawi Limited in Human Mutation
- Vol. 15 (4) , 381
Open AccessIdentification of a novel mutation (867delA) in the glucose-6-phosphatase gene in two siblings with glycogen storage disease type Ia with different phenotypes Communicated by: Mark H. Paalman Online Citation: Human Mutation, Mutation in Brief #304 (1999) Online http://journals.wiley.com/1059-7794/pdf/mutation/304.pdf
We identified a novel mutation (867delA) in the glucose-6-phosphatase gene of two siblings with glycogen storage disease type Ia. Although both siblings share the same mutations, their phenotype regarding adult height and hepatomegaly differs. In glycogen storage disease type Ia, substantial heterogeneity in phenotype is observed. So far, no evidence for a clear genotype-phenotype correlation has been found. Hum Mutat 15:381, 2000.
- 1 January 1999
- Published by Hindawi Limited in Human Mutation
- Vol. 13 (2) , 173
Glycogen storage disease type Ia: Four novel mutations (175delGG, R170X, G266V and V338F) identified
Deficient activity of glucose-6-phosphatase (G6Pase) causes glycogen storage disease type Ia (GSD Ia). We analysed the G6Pase gene of 16 GSD Ia patients using single strand conformation polymorphism (SSCP) analysis prior to automated sequencing of exon(s) revealing an aberrant SSCP pattern. In all GSD Ia patients we were able to identify mutations on both alleles of the G6Pase gene, indicating that this method is a reliable procedure to identify mutations. Four novel mutations (175delGG, R170X, G266V and V338F) were identified.
- 1 January 1999
- Published by Hindawi Limited in Human Mutation
- Vol. 13 (2) , 173
Glycogen storage disease type Ia: Four novel mutations (175delGG, R170X, G266V and V338F) identified
Deficient activity of glucose-6-phosphatase (G6Pase) causes glycogen storage disease type Ia (GSD Ia). We analysed the G6Pase gene of 16 GSD Ia patients using single strand conformation polymorphism (SSCP) analysis prior to automated sequencing of exon(s) revealing an aberrant SSCP pattern. In all GSD Ia patients we were able to identify mutations on both alleles of the G6Pase gene, indicating that this method is a reliable procedure to identify mutations. Four novel mutations (175delGG, R170X, G266V and V338F) were identified.